Article
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
Cancer cell - 9 Sept 2024
Xu Jiachen, Wan Rui, Cai Yiran, Cai Shangli, Wu Lin, Li Baolan, Duan Jianchun, Cheng Ying, Li Xiaoling, Wang Xicheng, Han Liang, Wu Xiaohong, Fan Yun, Yu Yan, Lv Dongqing, Shi Jianhua, Huang Jianjin, Zhou Shaozhang, Han Baohui, Sun Guogui, Guo Qisen, Ji Youxin, Zhu Xiaoli, Hu Sheng, Zhang Wei, Wang Qiming, Jia Yuming, Wang Ziping, Song Yong, Wu Jingxun, Shi Meiqi, Li Xingya, Han Zhigang, Liu Yunpeng, Yu Zhuang, Liu An-Wen, Wang Xiuwen, Zhou Caicun, Zhong Diansheng, Miao Liyun, Zhang Zhihong, Zhao Hui, Yang Jun, Wang Dong, Wang Yingyi, Li Qiang, Zhang Xiaodong, Ji Mei, Yang Zhenzhou, Cui Jiuwei, Gao Beili, Wang Buhai, Liu Hu, Nie Lei, He Mei, Jin Shi, Gu Wei, Shu Yongqian, Zhou Tong, Feng Jian, Yang Xinmei, Huang Cheng, Zhu Bo, Yao Yu, Yu Jianjun, Yao Sheng, Shen Runxi, Wang Zhijie, Wang Jie
Abstract excerpt
Stratification strategies for chemotherapy plus PD-1 inhibitors in advanced non-small-cell lung cancer (NSCLC) are critically demanded. We performed high-throughput panel-based deep next-generation sequencing and low-pass whole genome sequencing on prospectively collected circulating tumor DNA (ctDNA) specimens from 460 patients in the phase 3 CHOICE-01 study at different time points. We identified predictive...
Topics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Circulating Tumor DNA
- Lung Neoplasms
- Immune Checkpoint Inhibitors